title: A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus.
abstract: OBJECTIVE
  Decompensated chronic hyperglycemia often leads to late microvascular complications such as retinopathy, diabetic foot syndrome, and diabetic kidney disease. The aim of this study was to determine the concentration of vascular endothelial growth factor A (VEGF-A) and its receptors in patients with well-controlled diabetes.
  
  
  METHODS
  The study was conducted on 31 patients with well-controlled type 2 diabetes without micro- or macroangiopathy. Thirty healthy volunteers were enrolled in a control group. Serum concentrations of VEGF-A, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), fasting glucose, and lipid profiles were measured, and the plasma concentration of glycated hemoglobin (HbA1c) was determined.
  
  
  RESULTS
  No significant differences were observed between the concentration of VEGF-A, VEGFR1 or VEGFR2 in the subject group and that in the control group. Positive correlations were noted between the levels of VEGF-A, VEGFR2, and triglyceride, and there was a negative correlation between the levels of VEGFR2 and high-density lipoprotein (HDL)-cholesterol in the study group.
  
  
  CONCLUSIONS
  The concentrations of VEGF-A and its receptors 1 and 2 in patients with well-controlled diabetes are comparable to those of healthy individuals, which may indicate that appropriate control of glucose levels delays the occurrence of vascular complications. A negative correlation between VEGFR2 and HDL-cholesterol levels, and positive correlations between VEGF-A, VEGFR2, and triglyceride levels, suggest that lipid abnormalities occurring in diabetes may be involved in the modulation of angiogenesis.
authors.affiliation: Department of Pathophysiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland; Department of Obstetrics, Gynecology and Oncological Gynecology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland; Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Ruszkowska-Ciastek
authors.forename: Alina
authors.initials: A
authors.lastname: Sokup
authors.forename: Maciej W
authors.initials: MW
authors.lastname: Socha
authors.forename: Zofia
authors.initials: Z
authors.lastname: Ruprecht
authors.forename: Lidia
authors.initials: L
authors.lastname: Hałas
authors.forename: Barbara
authors.initials: B
authors.lastname: Góralczyk
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Góralczyk
authors.forename: Grażyna
authors.initials: G
authors.lastname: Gadomska
authors.forename: Danuta
authors.initials: D
authors.lastname: Rość
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood* / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C000588866:KDR protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2
keywords: Angiogenesis; Glycated hemoglobin (HbA1c); Lipid abnormalities; Type 2 Diabetes